tirzepatide in osa FDA's First GLP-1 Approval for Sleep Apnea May Reduce Reliance on CPAP Breakthrough Treatment for Obstructive Sleep

Tirzepatide is a dual GLP-1 and GIP receptor agonist that works by slowing stomach emptying, reducing hunger signals, and improving insulin sensitivityresulting in meaningful weight reduction for many patients

Side effects are rare and mild, usually limited to brief muscle soreness, local discomfort, or dizziness

Phymatous changes usually occur on the nose and are more common in men

Central obesity can be further classified into visceral and subcutaneous adipose compartments, where visceral obesity is independently associated with cardiovascular disease [55,56,57,58], and may play a key role in mediating cardiometabolic risk in OSA [56, 58,59,60,61,62]

Currently, Novo Nordisk sells Ozempic and Wegovy in India, while Eli Lilly and Company leads with Mounjaro (tirzepatide)